Transgenic Technology Unit

Transgenic Technology Unit /Laboratory (Established in 1996, the first inGreece)

Head:S. Haralambous, Research Associate ProfessorTel: +30 210 6478862 -210 6478854, e-mail:



The Transgenic Technology Unit (TTU) comprises a fully equipped laboratory and an area where the collection of the Transgenic (Tg), KO and mutant mouse lines are maintained under specific pathogen free (SPF) conditions. Our Tg mice collection are mainly HPI research products internationally recognized as human infectious, inflammatory and neurodegenerative diseases such as rheumatoid arthritis, multiple sclerosis, cachexia, inflammatory bowel disease. Moreover, modeling cardiovascular diseases, cancer and ageing are included in the running projects of the lab.

The main laboratory activity is to generate genetically modified mice by using cutting-edge transgenic technologies with the aim to establish models for human diseases, as well as to perform preclinical drug evaluations in terms of high quality services or research collaborations to the national and international research community.

Transgenic Technology Unit is included in the international map for transgenic core facilities ( and is a member of ISTT (International Society for Transgenic Technology) ( )

In TTU many therapeutic factors which have been already come on the market have been tested in one of the in-house transgenic mice collection of HPI, the established transgenic model for Rheumatoid Arthritis, human TNF transgenic mice, Tg 197 mouse line. ( )

TTU, with its results, has participated in an international survey of transgenic mouse core facilities conducted to establish performance standards for DNA microinjection

From 2005 TTU participates  in Master programs which take place in the Department of  Biology of the National & Kapodistrian University of Athens, with lectures related to Transgenesis.,


Head of the Lab: S. Haralambous, Research Associate Professor, Tel: +30 210 6478862 -210 6478854, e-mail:


Research Team

PhD student: N. Kavrohorianou, BSc Biology, HIP fellow, Τel: +30 210 6478 863, ext.865, e-mail:

PhD student:  M. Linou, Associate veterinarian of HPI, (External project), Τel: +30 210 6478 863, ext.865, e-mail:

Master student: I. Grivas, BSc Biology, (Master program, National & Kapodistrian University of Athens), Τel: +30 210 6478 863,

Graduate student: E. Malaktari, Biologist, University of Ioannina, Τel : +30 210 6478 863

Graduate student: M.Markogiannaki, Biologist, University of Ioannina, Τel : +30 210 6478 863


ResearchAssistant: I. Steriatou, BSc Biology, Tel: +30 210 6478 863

Technologist: F. Badounas, Τel : +30 210 6478 863, ext. 865, e-mail:

Animal Caretaker:A. Vagionas, Τel : +30 210 6478 865

Past Members/ Trainees (1996-   )

Akassoglou K., Alexopoulou S., Armaka M., Voliotis A., Giannakopoulou A., Evangelidou M., Emmanouil M., Zoupa A., Kaminari A., Katouna A., Kefalaki A., Labropoulou S., Manta A., Moraiti L., Douni E., Papandreou S., Pissas G., Politis P., Taoufik E., Tzeveleki V., Tsakogiannis D., Fatourou O.

Specialized Services

Specialized Services


  • Preclinical evaluation our in house models of human diseases
  • Generation of transgenic mice upon request or in collaboration projects.
  • Genotyping and characterization of transgenic mice
  • Storage and archiving of mutant strains (cryopreservation of mouse embryo and sperm (in progress)
  • Embryo Rederivation, for speed production of mouse colonies and  transportation
  • Congenic strains
  • Training


List of Transgenic and Mutant Mice








1.       Haralambous S., L. Probert, M. Mastrangelo, G. Kollias and L. Molony. Adhesion molecule blockade modulates the development of TNF-triggered arthritis in transgenic mice. Eur. Cytokine Netw., 1996, 7: 293

2.       Probert L., K. Akassoglou, L. Alexopoulou, E. Douni, S. Haralambous, S. Hill, G. Kassiotis, D. Kontogiannis, M. Pasparakis, D. Plows, and G. Kollias (1996) Dissection of the pathologies induced by transmembrane and wild type tumour necrosis factor in transgenic mice. Journal of Leucocyte Biology, 59: 518-525.

3.       Kollias G, Akassoglou K, Alexopoulou L, Douni E, HaralambousS, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L.(1997). Animal models of TNF-mediated inflammation. J. of Leukocyte Biology   p: 9

4.       Douni, K. Akassoglou, L. Alexopoulou, S. Georgopoulos, S. Haralambous, S.Hill, G. Kassiotis, D. Kontogiannis, M. Pasparakis, D. Plows, L. Probert, and G. Kollias (1996) Transgenic and knockout analyses of the role of TNF in Immune Regulation and disease Pathogenesis. J Inflammation 47: 27-38.

5.       Platts L.A.M., S. Haralambous, M.V.J. Hukkanen, S.S. Gross, G. Kollias, J.M. Polak (1997). Inducible nitric oxide synthase and cyclooxygenase are expressed in human-TNFα transgenic mice which develop arthritis spontaneously. J. Pathology 181: A42

6.       Markus Neurath, Ivan Fuss, Manolis Pasparakis, Lena Alexopoulou, SylvaHaralambous, Karl-Herman Meyerzum Buschenfelde, Warren Strober and G. Kollias (1997) Predominant pathogenic role of tumor necrosis factor α in experimental colitis in mice. Eur. J. Immunol. 27:1743-1750.

7.       P.P Sfikakis, S. Haralambous, G. Kollias. Effects of Glucocorticoid and Methotrexate administration on the Tg197 TNF-transgenic mouse model of chronic inflammatory polyarthritis,(1998). Arthritis and Rheumatism 41(9):100

8.       Z. Kaymakcalan, S. Haralambous, D. Tracey,   R. Kamen,   J. Salfed   and   G. Kollias. (1998). Prevention of Polyarthritis in human TNF transgenic mice by D2E7: A fully human anti-humanTNF monoclonal antibody. Arthritis and Rheum.41(9):390-392

9.       Haralambous S.,  Plows  D. and  G. Kollias. (1998). Attenuation  of  transgenic  TNF-triggered arthritis in type I IL-1 receptor knockout mice. Eur. Cyt.Network 9 (3): 421-

10.   M.F.Neurath, K. Hildner, C. Becker, J.F Schlaak, K. Barbuleskcu, T. Germann, E. Schmitt, P. Schirmacher, S. Haralambous, M. Pasparakis, K. Meyer Zum Buschenfelde, G. Kollias and E. Marker-Hermann (1999)  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115 (1): 42-55.


2000- 2010

11.   Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G, Smolen J. (2001). Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. Dec; 44 (12):2888-2898.

12.   Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002). Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin Arthritis Rheum. Mar;46(3):785-792.

13.   Hukkanen M, Platts LA, Haralambous S, Ainola M, Konttinen YT, Kollias G, Polak JM. (2003). Induction of inducible nitric oxide synthase, argininosuccinate synthase, and GTP cyclohydrolase I in arthritic joints of human tumor necrosis factor-alpha transgenic mice. J Rheumatol. Apr;30(4):652-659.

14.   Aidinis V, Plows D, Haralambous S, Armaka M, Papadopoulos P, Kanaki MZ, Koczan D, Thiesen HJ, Kollias G. (2003) Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res Ther.;5(3):R140-157.

15.   Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G. (2004). Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther.;6(1):R65-R72.

16.   Tseveleki V, Bauer J, Taoufik E, Ruan C, Haralambous S, Lassmann H, and Probert L.  (2004). c-FLIP overexpression in T cells drives Th2 effector responses and promotes immunoregulation in experimental autoimmune encephalomyelitis. J. Immunology, 173: 6619-6626.

17.   Hayer S., Toshidast-Akrad M., HaralambousS. Jahn-Schmid B., Skriner K., Trembleau S., Dumortier H., Pinol-Roma S., Redlich K., Schett G., Muller S. Kollias G., Smolen J. and Steiner G. (2005). Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (RA33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-RA33 Autoantibodies in TNF-α Transgenic Mice. J. Immunology, 175: 8327-8336.

18.   Taoufik E., Tseveleki V., Euagelidou M., Emmanouil M., Voulgari Kokota A., Haralambous S., and Probert L. (2008). Positive and negative implications of TNF neutralization for the pathogenesis of multiple sclerosis.  Neurogenerative diseases, 5(1): 32-7

19.   Marlon P. Quinones, Yogesh Kalkonde, Carlos A. Estrada, Fabio Jimenez, Robert Ramirez, Hernan Martinez, Matthias Mack, Robert L. Reddick, Shivani Maffi, Sylva Haralambous, Lelsey Probert, Sunil K. Ahuja, Seema S. Ahuja (2008). Role of Astrocytes and Chemokine Systems in Acute TNF<alpha> induced Demyelinating Syndrome: CCR2-dependent Signals promote Astrocyte Activation and Survival via NF-<kappa>B and Akt. Mol.  Cell Neurosc.37(1):96-109

20.   Mattheolabakis G., Taoufik E., Haralambous S, Roberts ML, Avgoustakis K.(2008). In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm  71(2): 190-195.

21.   Kavrochorianou N., Evangelidou M., Tovey M., Thyphronitis G., and Haralambous S. (2009). A transgenic animal model for the investigation of the role of type I interferons in T lymphocyte biology. Cytokine,48(1-2):47-48

22.   Kyriaki Ioannou, Pinelopi Samara, Nadia Kavrochorianou, Christina Bega, George Thyphronitis, Sylva Haralambous, Ourania Tsitsilonis. (2010) The C-Terminal decapeptide of prothymosin α induces a TH1-Type immune response in vitro and retards tumor growth in vivo.Proceedings of the 8th Joint Conference of the International Cytokine Society and the international Society for Interferon and cytokine research (on line)


More than 40 confidential research projects with national and international companies, many collaborative research projects with academia and specialized services upon request have been conducted.


Horizontal Collaborations in HPI

Many national and international Pharmaceutical companies

External collaborations









/* Style Definitions */
{mso-style-name:”Table Normal”;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-fareast-font-family:”Times New Roman”;
mso-bidi-font-family:”Times New Roman”;